Production (Stage)
Alto Neuroscience, Inc.
ANRO
$3.03
$0.103.41%
NYSE
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -13.06% | -35.52% | -83.60% | -85.04% | -84.20% |
| Total Depreciation and Amortization | 76.29% | 51.79% | 93.65% | 0.89% | 12.79% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 19.64% | 159.29% | 348.64% | 112.23% | 298.77% |
| Change in Net Operating Assets | -1,727.06% | 108.56% | 234.05% | 138.33% | 73.87% |
| Cash from Operations | -50.74% | -12.99% | -51.01% | -76.25% | -45.97% |
| Capital Expenditure | 89.29% | -43.75% | -2,237.21% | -529.63% | -966.67% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | 89.29% | -43.75% | -2,237.21% | -529.63% | -966.67% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -99.86% | 68.97% | -38.53% | 41.86% | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 81.98% | 34.11% | 2,183.33% | -213.83% | -- |
| Cash from Financing | -93.22% | -99.89% | 2,587.76% | -358.82% | 438.24% |
| Foreign Exchange rate Adjustments | -340.00% | 50.00% | -138.89% | 54.55% | 73.68% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -106.06% | -143.10% | -47.54% | -81.80% | 607.43% |